Results 11 to 20 of about 2,108 (191)

Occlusive retinal vasculitis associated with intravitreal Faricimab injections [PDF]

Journal of Ophthalmic Inflammation and Infection
Purpose We describe a case of occlusive vasculitis associated with intravitreal Faricimab (Vabysmo) injections. Methods A retrospective case report. Results A 52-year old man treated with monthly Faricimab injections for diabetic macula oedema presented ...
Felix F. Reichel, Peter Kiraly, Roopa Vemala, Stella Hornby, Samantha R. De Silva, M. Dominik Fischer   +5 more
doaj   +3 more sources

Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison [PDF]

Drug Target Insights
Objectives: To assess through an indirect treatment comparison (ITC) the potential benefit of faricimab over the anti-vascular endothelial growth factor (VEGF) real-life scenario, hereby defined standard of care (SoC), in Italy, that is, aflibercept ...
Carlotta Galeone, Federica Turati, Massimo Nicolò, Mariacristina Parravano, Stela Vujosevic, Laura Bianchino, Emilia Sicari, Paolo Lanzetta   +7 more
doaj   +3 more sources

Dynamics of Treatment Response to Faricimab for Diabetic Macular Edema [PDF]

Bioengineering
This study analyzes the dynamics of short-term treatment response to the first intravitreal faricimab injection in eyes with diabetic macular edema (DME). This retrospective, single-center, clinical trial was conducted at the Department of Ophthalmology,
Katrin Fasler, Daniel R. Muth, Mariano Cozzi, Anders Kvanta, Magdalena Rejdak, Frank Blaser, Sandrine A. Zweifel   +6 more
doaj   +3 more sources

Sterile Intraocular Inflammation Associated With Faricimab [PDF]

JAMA Ophthalmology
ImportanceRandomized clinical trials are conducted to establish both drug safety and efficacy. However, evidence of adverse events associated with these drugs in the clinical practice setting can be of value at generating hypotheses regarding less common safety issues, even if causality cannot be determined.ObjectiveTo present and analyze cases of ...
Cozzi, Mariano, Ziegler, Alexander, Fasler, Katrin, Muth, Daniel Rudolf, Blaser, Frank, Zweifel, Sandrine Anne   +5 more
openaire   +5 more sources

Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review [PDF]

International Journal of Retina and Vitreous
Background To systematically review the real-world outcomes of intravitreal faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy and safety in clinical settings. This study was conducted due to
Nasratullah Nasimi, Safiullah Nasimi, Jakob Grauslund, Anna Stage Vergmann, Yousif Subhi   +4 more
doaj   +2 more sources

Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema [PDF]

American Journal of Ophthalmology Case Reports
Purpose: More information is emerging on faricimab-svoa (faricimab) used for etiologies beyond wet age-related macular degeneration (AMD) and diabetic macular edema (DME), including ongoing trials for use in macular edema following retinal vein occlusion
Justin Hanson, Marcus Yamamoto, Edmund Tsui, Irena Tsui   +3 more
doaj   +2 more sources

Conbercept Treatment for Heart‐Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti‐VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA [PDF]

Clinical Case Reports, Volume 13, Issue 10, October 2025.
A 63‐year‐old male with a history of hypertension and diabetes developed acute vision loss, which was attributed to macular neovascularization secondary to hypertensive retinopathy. Optical coherence tomography angiography revealed unusual heart‐shaped, intertwined vascular nets, informing the choice of Conbercept for intravitreal injection.
Shangkun Ou, Feiping Shi, Minqing Cai, Yiming Wu   +3 more
wiley   +3 more sources

Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA [PDF]

International Journal of Retina and Vitreous
Background To analyze the therapeutic response to faricimab 6 mg/0.05 ml in eyes with neovascular AMD (nAMD) with refractory intra- and/or subretinal fluid due to choroidal neovascularization (CNV), previously unresponsive to 4 mg monthly aflibercept and
Anna Heinke, Alexandra Warter, Ines D. Nagel, Akshay Agnihotri, Nehal Nailesh Mehta, Carlo Miguel B. Galang, Daniel N. Deussen, Dirk-Uwe G. Bartsch, Lingyun Cheng, Henry A. Ferreyra, William R. Freeman   +10 more
doaj   +2 more sources

Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography

Pharmaceutics
Our study aimed to assess the anatomical changes in the retina, including the assessment of the reduction of diabetic macular edema (DME) on optical coherence tomography (OCT) and the improvement of retinal microvascular parameters, defined by the ...
Dorota Śpiewak, Łukasz Drzyzga, Mariola Dorecka, Katarzyna Witek, Dorota Wyględowska-Promieńska   +4 more
doaj   +4 more sources

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration [PDF]

Clinical Ophthalmology
Abraham Hang, Taylor Ngo, Jaipreet Singh Virk, Kareem Moussa, Ala Moshiri, Parisa Emami-Naeini, Susanna S Park Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USACorrespondence: Susanna S Park ...
Hang A, Ngo T, Virk JS, Moussa K, Moshiri A, Emami-Naeini P, Park SS   +6 more
doaj   +3 more sources